Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer

Human Pathology

Volumn 42, Issue 10, 2011, Pages 1499-1504

  Zhu, Xiaoli ^a   Lu, Yongming ^a   Lu, Hongfen ^a   Yang, Wentao ^a   Tu, Xiaoyu ^a   Cai, Xu ^a   Zhou, Xiaoyan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; Chromosome 17; Fluorescence in situ hybridization; HER2; Immunohistochemistry; Polysomy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INVASION; CHROMOSOME 17; CHROMOSOME 17 POLYSOMY; CHROMOSOME ANALYSIS; CHROMOSOME DISORDER; FLUORESCENCE IN SITU HYBRIDIZATION; FREQUENCY ANALYSIS; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ANEUPLOIDY; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 80053180825     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.04.023     Document Type: Article

References (35)

1. N.C. Popescu, C.R. King, and M.H. Kraus Localization of the human erbB-2 gene on normal and rearranged chromosome 17 to bands q12-21.32 Genomics 4 1989 362 366
2. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene Science 235 1987 177 182 (Pubitemid 17231334)
3. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712 (Pubitemid 19147683)
4. M.F. Press, D.J. Slamon, and K.J. Flom Evaluation of HER2/neu gene amplification and overexpression J Clin Oncol 20 2002 3095 3105
5. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
6. C.L. Vogel, M.A. Cobleigh, and D. Tripathy Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726 (Pubitemid 34111379)
7. J.S. Ross, J.A. Fletcher, and G.P. Linette The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 2003 307 325 (Pubitemid 36929717)
8. M. Piccart, C. Lohrisch, A. Di Leo, and D. Larsimont The predictive value of HER2 in breast cancer Oncology 61 Suppl 2 2001 83 91
9. M. Bilous, M. Dowsett, and W. Hanna Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 2003 173 182 (Pubitemid 36245750)
10. I.O. Ellis, J. Bartlett, and M. Dowsett Updated recommendations for HER2 testing in the UK J Clin Pathol 57 2004 233 237 (Pubitemid 38338829)
11. M. Dowsett, J. Bartlett, and J.O. Ellis Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J Pathol 199 2003 418 423 (Pubitemid 36411217)
12. H. Yaziji, L.C. Goldstein, and T.S. Barry HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 2004 1972 1977 (Pubitemid 38544278)
13. S. Wang, M.H. Saboorian, and E. Frenkel Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays J Clin Pathol 53 2000 374 381 (Pubitemid 30256906)
14. S. Wang, H. Saboorian, and E.P. Frenkel Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implications for clinical assessment of HER-2/neu status Mod Pathol 15 2002 137 145 (Pubitemid 34171323)
15. D. Varshney, Y.Y. Zhou, S.A. Geller, and R. Alsabeh Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay Am J Clin Pathol 121 2004 70 77 (Pubitemid 38090156)
16. C. Hyun, H. Lee, and K. Kim The effect of chromosome 17 polysomy on HER2/neu status in breast cancer J Clin Pathol 61 2008 317 321 (Pubitemid 351354237)
17. R. Torrisi, N. Rotmensz, and V. Bagnardi HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17 Eur J Cancer 43 2007 2339 2344 (Pubitemid 47625971)
18. J.M.S. Bartlett, J. Reeves, and P. Stanton Evaluating HER2 amplification and overexpression in breast cancer J Pathol 195 2001 422 428 (Pubitemid 33069666)
19. S.R. McCormick, T.J. Lillemoe, and J. Beneke HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays Am J Clin Pathol 117 2002 935 943 (Pubitemid 34564351)
20. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 2007 18 43 (Pubitemid 46174133)
21. N. Sneige, B. Liu, G. Yin, Y. Gong, and B.K. Arun Correlation of cytologic findings and chromosomal instability detected by fluorescence in situ hybridization in breast fine-needle aspiration specimens from women at high risk for breast cancer Mod Pathol 19 2006 622 629
22. M. Salido, I. Tusquets, and J.M. Corominas Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry Breast Cancer Res 7 2005 267 273
23. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1977 159 174 (Pubitemid 8054849)
24. M.A. Owens, B.C. Horten, and M.M. Da Silva HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5 2004 63 69 (Pubitemid 38821193)
25. H. Tsuda, F. Akiyama, and H. Terasaki Detection of HER-2/neu(cerb-B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemiscal HER-2 overexpression Cancer 92 2001 2965 2974 (Pubitemid 33136190)
26. G. Pauletti, W. Godolphin, and M.F. Press Detection and quantitation of Her-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 13 1996 63 72 (Pubitemid 26248546)
27. G. Pauletti, S. Dandekar, and H. Rong Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry J Clin Oncol 21 2000 3651 3664
28. T.W. Jacobs, A.M. Gown, and H. Yaziji Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of Her-2/neu in breast cancer J Clin Oncol 17 1999 1974 1982 (Pubitemid 29318824)
29. R.E. Jimenez, T. Wallis, and P. Tabasczka Determination of Her-2/neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization Mod Pathol 13 2000 37 45 (Pubitemid 30077902)
30. Y. Ma, L. Lespagnard, and V. Durbecq Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice Clin Cancer Res 11 2005 4393 4399 (Pubitemid 40825629)
31. A.D. Watters, J.J. Going, and T.G. Cooke Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma Breast Cancer Res Treat 77 2003 109 114 (Pubitemid 36197611)
32. S.S. Shah, Y. Wang, J. Tull, and S. Zhang Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma Diagn Mol Pathol 18 2009 30 33
33. P. Lal, P.A. Salazar, M. Ladanyi, and B. Chen Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification J Mol Diagn 5 2003 155 159 (Pubitemid 36974726)
34. M. Hofmann, O. Stoss, and T. Gaiser Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy J Clin Pathol 61 2008 89 94 (Pubitemid 351158232)
35. I. Vanden Bempt, P. Van Loo, M. Drijkoningen, and C. De Wolf-Peeters Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing J Clin Oncol 26 2008 4869 4874